ClinicaliQ Trial Snapshot
- INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) — Recruiting • Phase III • Oncology • NCT07429266.
- What is being tested: Sapablursen, an investigational antisense oligonucleotide, is being evaluated as an add-on therapy to standard of care treatment in patients with polycythemia vera across a multi-part blinded study design.
- Patient eligibility overview: The trial enrolls participants with polycythemia vera who are currently receiving standard-of-care therapy, with eligibility criteria refined across sequential study parts to optimise safety and efficacy assessment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, & Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.
Eligibility Snapshot
- : 1. Meet revised 2022 World Health Organization (WHO) and 2022 International Consensus Classification criteria for the diagnosis of PV.
- Participants must be phlebotomy-dependent. 3. Hct less than (
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.